If this email is not displaying properly or to share with a colleague, please
View as Webpage
|
|
What to Expect from the New PCSS Grant Cycle?
|
|
PCSS is beginning a new three-year grant, funded by the Substance Abuse and Mental Health Services Administration (SAMHSA), and while we will continue to hold live webinars, develop tool kits, offer free clinical mentoring, and provide free MAT waiver trainings, we are also planning some exciting changes.
|
|
- PCSS Exchange: an online interdisciplinary training/mentoring forum, led by a clinical expert to be held every two weeks on a variety of topics.This will be a collaborative effort with several PCSS partner organizations with the Addiction Technology Transfer Centers (ATTC) working with AAAP to lead this effort. Anyone will be able to participate in the PCSS Exchange. We'll have more news in the coming months.
- Expanded stakeholders: PCSS has expanded its partner organizations to broaden its scope to include allied professionals, including social workers and counselors, peer recovery coaches, nurses, medical technicians, and others. New partners include:
- American Pharmacist Association
- Council on Social Work Education
- National Council for Behavioral Health
- The National Judicial College
- Physician Assistant Education Association
- Society for Academic Emergency Medicine
- Expand PCSS Implementation Initiative: The goal of PCSS Implementation is to support the scale up of MAT in diverse healthcare settings. Facilitation teams led by PCSS partners AAAP, AOAAM, and AMERSA will identify at least one clinic per year to provide intensive support and will be expanded to include emergency departments interested in implementing buprenorphine induction with American College of Emergency Physicians and Society of Academic Emergency Medicine.
- Training of Trainers: This program will be developed to enhance the number of implementation facilitation teams capable of supporting healthcare organizations who wish to implement MAT. A pilot is being developed this year. More information to come.
|
|
Tell Your Colleagues About PCSS!
|
|
Not everyone knows about the free resources, trainings, mentoring and MAT waiver trainings that PCSS offers. Please let your colleagues know about PCSS by sending them the link at the top of this email.
Together we
can
make a difference!
|
|
|
American Academy of Addiction Psychiatry
|
|
The
American Academy of Addiction Psychiatry, as part of its 35th Annual Meeting and Scientific Symposium in San Diego, CA, is offering three pre-courses:
- Practical Guide to Offering Office-Based Opioid Treatment: an interactive 4.5-hour course designed for physicians, nurse practitioners, PA’s, pharmacists, nurses, social workers, psychologists and healthcare professionals who are involved in a MAT practice and want to expand their expertise and comfort level in treating patients with opioid use disorder (OUD). Dec. 4, 2019
- Advanced Addiction Psychopharmacology: an intensive two-day, 12-hour course designed for physicians, nurse practitioners and PA’s who have a foundation in prescribing medication for patients with substance use disorders but would like a deeper understanding of these pharmacologies. Dec. 4-5, 2019
- Addictions and Their Treatment: a 20.75-hour, 2 1/2-day course designed for anyone who is interested in learning more about substance use disorders and to help prepare for subspecialty certification in Addiction Psychiatry and Maintenance of Certification. It is recommended for PGY-V residents, general psychiatry residents, and periodically for all academic and treatment personnel to stay updated on the most recent trends in the addiction field. Dec. 2-5, 2019
|
|
American Medical Association
|
|
The American Medical Association (AMA) and Manatt Health released an analysis earlier this month identifying effective state policies used to combat the opioid epidemic.
The analysis looked at the response to the epidemic in four states and determined which polices increased access to evidence-based treatment for people with a substance use disorder. The AMA and Manatt originally reviewed policies in Colorado, Mississippi, North Carolina and Pennsylvania and used those analyses along with additional work to develop recommendations for state health care policy.
The national roadmap highlights six key areas where regulators, policymakers, and other stakeholders can take action:
- Improving access to evidence-based treatment for opioid use disorder. Remove prior authorization and other barriers to medication-assisted treatment (MAT) for opioid use disorder—and ensure MAT is affordable.
- Enforcing parity laws. Increase oversight and enforcement of mental health and substance use disorder parity laws.
- Addressing network adequacy and enhancing workforce. Ensure adequate networks that allow for timely access to addiction medicine physicians and other health care professionals; this includes payment reforms, collaborative care models, and other efforts to bolster and support the nation’s opioid use disorder treatment workforce.
- Expanding pain management options. Enhance access to comprehensive pain care, including non-opioid and non-pharmacologic options.
- Improving access to naloxone. Reduce harm by expanding access to the overdose-reversing drug and coordinating care for patients in crisis.
- Evaluating policy success and barriers. Evaluate policies and outcomes to identify what is working, building on successful efforts and identifying policies and programs that might need to be revised or rescinded. [Read more]
|
|
National Institutes of Health Newsletter
American Journal of Public Health
JAMA Internal Medicine
JAMA Pediatrics
Journal of Substance Abuse Treatment
Pediatrics
The Pew Chartible Trusts: Stateline
The American Journal on Addictions
*Requires a subscription or payment to view full article
|
|
Funding for this initiative was made possible (in part) by grant no.
1H79TI081968
from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
|
|
|
|
|
|
|
